Specifically, selective ER modulators (SERMs, i.e. tamoxifen), selective estrogen receptor degraders (SERDs, i.e. fulvestrant), and aromatase inhibitors (AIs, i.e. letrozole) have been approved and largely used as adjuvant treatments in ERα-positive BC patients [12]. Here, ESR1 is linked to breast cancer.